ZDF German Television: From historical conflicts to family ties: New8 showcases second slate of international drama series
26.3.2025 15:32:26 CET | news aktuell GmbH | Press release
Following the success of the first series of New8, the new projects of this international drama collaboration of eight public broadcasters were presented today at Series Mania in Lille. The partners of New8 – SVT (Sweden), DR (Denmark), YLE (Finland), RÚV (Iceland), NRK (Norway), VRT (Flanders, Belgium), NPO (Netherlands) and ZDF (Germany) – have coproduced eight drama series since the start of the collaboration in autumn 2023. The aim of New8 is to coproduce high-quality series across national borders that reflect the values of public service media and appeal to a broad audience.
The projects selected for the second slate once again present an exciting variety of genres and topics. These range from historical and social drama series to family stories, crime series and mystery series:
"Breendonk"(VRT, Belgium, 6x54 minutes), "Phoenix" (ZDF, Germany, 6x45 minutes), "The Machine", (NPO/BNNVARA, The Netherlands, 6x54 minutes), "Henki" (NRK, Norway, 6x45 minutes), "Cold Song" (SVT, Sweden, 6x45 minutes), "Generations" (DR, Denmark, 6x60 minutes), "Death of a Horse" (RÚV, Iceland, 6x52 minutes) and "The Dark Ones" (ZDF, Germany, 6x45 minutes).
The first eight series of the coproduction initiative have been already produced: "Vanguard" (SVT), "Elixir" (NPO), "Queen of fucking everything" (YLE), "Holmlia Love" (NRK), "Other People's Money" (DR/ZDF), "This is not a murder mystery" (VRT), "Push" and "Kabul" (ZDF). Some of them have already been honoured nationally and internationally. These include ZDF's New8 series "Push" (German Television Award 2024) and ‘"Kabul" (Series Mania 2025 – International Competition), as well as "Other People's Money" (Berlinale 2025 - Panorama section) and "Generations" (Series Mania 2025 – International Competition), both of which were brought into the cooperation by the Danish broadcaster DR.
The programs in detail and more Information.
Kontakt: ZDF-Kommunikation, pressedesk@zdf.de
Follow us LinkedIn.
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
FRITZ: YouGov survey in 14 countries: Trust in router manufacturers from different regions European consumers mistrust Chinese routers29.6.2026 10:00:00 CEST | Press release
More than half of consumers in Norway mistrust routers from Chinese manufacturers (59%) Many mistrust devices made in the USA European routers enjoy a high level of trust across Europe (60%) For half of Europeans (55%), the ‘Made in Europe’ label important to when making a purchase
93% of Europe's Internet Traffic Flows Through Routers – Yet No One Is Paying Attention: Study Demands Action on Digital Sovereignty24.6.2026 10:00:00 CEST | Press release
Berlin, 24 June 2026 – The Sovereignty Alliance for European Network Technology (SAFENet), together with the Innovate Europe Foundation (IE.F) and Berlin-based consultancy iconomy, publishes a new foundational study revealing that 93% of European internet traffic flows through routers and yet the EU has no sovereignty framework for this key component of the digital ecosystem. Meanwhile, Chinese manufacturers already control 37% of the market.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom